Hennion & Walsh Asset Management’s Quince Therapeutics QNCX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-155	Closed	-$48K	–	835
2023 Q1	$48K	Sell	155 -6	-4%	-$1.17K	﹤0.01%	772
2022 Q4	$20K	Sell	161 -231	-59%	-$38.6K	﹤0.01%	765
2022 Q3	$104K	Sell	392 -16	-4%	-$6.09K	0.01%	753
2022 Q2	$181K	Sell	408 -15	-4%	-$10.6K	0.01%	731
2022 Q1	$523K	Sell	423 -7	-2%	-$9.53K	0.03%	505
2021 Q4	$1.08M	Sell	430 -17	-4%	-$104K	0.05%	338
2021 Q3	$8.2M	Buy	447 +38	+9%	+$604K	0.43%	51
2021 Q2	$4.33M	Buy	409 +132	+48%	+$1.11M	0.23%	108
2021 Q1	$2M	Buy	+277	New	+$1.99M	0.12%	230

Other funds holding QNCX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KAM

Knightsbridge Asset Management Newport Beach, California $743M AUM 28.33% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hennion & Walsh Asset Management's QNCX Position: Q2 2023 in Review

Hennion & Walsh Asset Management sold out of Quince Therapeutics (QNCX) in Q2 2023, closing a stake of 155 shares — an estimated $48K sold.

Hennion & Walsh Asset Management first reported a position in QNCX in Q1 2021 and held it in 9 quarters. The position peaked at $8.2M in Q3 2021. 38 funds tracked by Wall St. Rank hold QNCX as of Q2 2023.

Hennion & Walsh Asset Management reported no remaining Quince Therapeutics position as of Q2 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 155 Quince Therapeutics shares in Q2 2023, an estimated $48K.
Hennion & Walsh Asset Management first reported a position in Quince Therapeutics in Q1 2021 and held it in 9 quarters.
Hennion & Walsh Asset Management's Quince Therapeutics position peaked at $8.2M in Q3 2021.
38 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.